Inactive Instrument

Highlights Lifestyle Delivery Systems Inc Canadian Securities Exchange

Equities

CA53224Y1043

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 29	CI
Core One Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 03	CI
Core One Labs Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-28	CI
Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer?s and Parkinson's Disease	23-08-04	CI
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023	23-08-03	CI
Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer?s and Parkinson?s Disease	23-07-28	CI
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process	23-07-12	MT
Core One's Vocan Files International Patent For Breakthrough Proprietary Biosynthetic Psilocybin Production Method	23-07-10	MT
Core One Labs Inc. Applauds FDA's Draft Guidance on Clinical Trials for Psychedelic Drugs	23-06-27	CI
Core One Labs Says in Talks with Multiple Companies to Supply Psilocybin; COOL Gained 15% on Friday	23-05-08	MT
Core One Labs Inc. in Talks with Multiple Companies to Supply Psilocybin	23-05-05	CI
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization	23-05-02	MT
Core One Labs Completes Synthetic Production of Psilocin at GMP Certified Manufacturing Facility; Surges Nearly 26% in Frankfurt Trading	23-04-24	MT
Core One Labs Applauds Study Linking Psychedelic Treatment to Substantial Reduction in Alcohol Misuse & Ptsd Symptoms in Us Special Operations Forces Veterans	23-04-04	CI
Core One Labs Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Core One Labs' Buys GMP Drug Inc.; Says "Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution	23-01-16	MT
Core One Labs Inc. completed the acquisition of GMP Drug Inc. for CAD 3.5 million.	23-01-12	CI
Core One Labs Inc. acquired GMP Drug Inc. for CAD 3.5 million.	23-01-12	CI
Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin	22-11-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lifestyle Delivery Systems Inc Canadian Securities Exchange

Equities

CA53224Y1043

Highlights

Filters